P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

• S. Yazji,
• S. Hamburger,
• Y. Wang,
• S. Yavrom,
• A. Pietrofeso,
• R. Bliss,
• J. B. Breitmeyer,
• M. Dreyling,
• M. Wang

Affiliations

S. Yazji

1 Oncternal Therapeutics, Inc., San Diego, CA

S. Hamburger

1 Oncternal Therapeutics, Inc., San Diego, CA

Y. Wang

1 Oncternal Therapeutics, Inc., San Diego, CA

S. Yavrom

1 Oncternal Therapeutics, Inc., San Diego, CA

A. Pietrofeso

1 Oncternal Therapeutics, Inc., San Diego, CA

R. Bliss

2 Veristat, LLC, Southborough, MA, United States of America

J. B. Breitmeyer

1 Oncternal Therapeutics, Inc., San Diego, CA

M. Dreyling

3 University of Munich, Munich, Bavaria, Germany

M. Wang

4 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America